<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35240944</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2222-1751</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Emerging microbes &amp; infections</Title>
          <ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Carbapenemase-producing <i>Pseudomonas aeruginosa</i> -an emerging challenge.</ArticleTitle>
        <Pagination>
          <StartPage>811</StartPage>
          <EndPage>814</EndPage>
          <MedlinePgn>811-814</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2048972</ELocationID>
        <Abstract>
          <AbstractText>Carbapenem-resistant <i>Pseudomonas aeruginosa</i> (CR-PA) is a major healthcare-associated pathogen worldwide. In the United States, 10-30% of <i>P. aeruginosa</i> isolates are carbapenem-resistant, while globally the percentage varies considerably. A subset of carbapenem-resistant <i>P. aeruginosa</i> isolates harbour carbapenemases, although due in part to limited screening for these enzymes in clinical laboratories, the actual percentage is unknown. Carbapenemase-mediated carbapenem resistance in <i>P. aeruginosa</i> is a significant concern as it greatly limits the choice of anti-infective strategies, although detecting carbapenemase-producing <i>P. aeruginosa</i> in the clinical laboratory can be challenging. Such organisms also have been associated with nosocomial spread requiring infection prevention interventions. The carbapenemases present in <i>P. aeruginosa</i> vary widely by region but include the Class A beta-lactamases, KPC and GES; metallo-beta-lactamases IMP, NDM, SPM, and VIM; and the Class D, OXA-48 enzymes. Rapid confirmation and differentiation among the various classes of carbapenemases is key to the initiation of early effective therapy. This may be accomplished using either molecular genotypic methods or phenotypic methods, although both have their limitations. Prompt evidence that rules out carbapenemases guides clinicians to more optimal therapeutic selections based on local phenotypic profiling of non-carbapenemase-producing, carbapenem-resistant <i>P. aeruginosa</i>. This article will review the testing strategies available for optimizing therapy of <i>P. aeruginosa</i> infections.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tenover</LastName>
            <ForeName>Fred C</ForeName>
            <Initials>FC</Initials>
            <AffiliationInfo>
              <Affiliation>Cepheid, Sunnyvale, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nicolau</LastName>
            <ForeName>David P</ForeName>
            <Initials>DP</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gill</LastName>
            <ForeName>Christian M</ForeName>
            <Initials>CM</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Emerg Microbes Infect</MedlineTA>
        <NlmUniqueID>101594885</NlmUniqueID>
        <ISSNLinking>2222-1751</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.2.6</RegistryNumber>
          <NameOfSubstance UI="D001618">beta-Lactamases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.2.6</RegistryNumber>
          <NameOfSubstance UI="C063912">carbapenemase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024881" MajorTopicYN="Y">Drug Resistance, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011552" MajorTopicYN="Y">Pseudomonas Infections</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011550" MajorTopicYN="Y">Pseudomonas aeruginosa</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001618" MajorTopicYN="N">beta-Lactamases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Pseudomonas aeruginosa</Keyword>
        <Keyword MajorTopicYN="N">beta-lactamase</Keyword>
        <Keyword MajorTopicYN="N">beta-lactamase inhibitor</Keyword>
        <Keyword MajorTopicYN="N">carbapenemase</Keyword>
        <Keyword MajorTopicYN="N">carbapenems</Keyword>
        <Keyword MajorTopicYN="N">susceptibility testing</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35240944</ArticleId>
        <ArticleId IdType="pmc">PMC8920394</ArticleId>
        <ArticleId IdType="doi">10.1080/22221751.2022.2048972</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Horcajada JP, Montero M, Oliver A, et al. . 
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019 Sep 18;32(4):e00031–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6730496</ArticleId>
            <ArticleId IdType="pubmed">31462403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M-G, Liu Z-Y, Liao X-P, et al. . 
Retrospective data insight into the global distribution of carbapenemase-producing Pseudomonas aeruginosa. Antibiotics (Basel). 2021 May 9;10(5):548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8151531</ArticleId>
            <ArticleId IdType="pubmed">34065054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Orphaly M, Hadi HA, Eltayeb FK, et al. . 
Epidemiology of multidrug-resistant Pseudomonas aeruginosa in the Middle East and North Africa region. mSphere. 2021 May 19;6(3):e00202–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8265635</ArticleId>
            <ArticleId IdType="pubmed">34011686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiner-Lastinger LM, Abner S, Edwards JR, et al. . 
Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol. 2020 Jan;41(1):1–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8276252</ArticleId>
            <ArticleId IdType="pubmed">31767041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woodworth KR, Walters MS, Weiner LM, et al. . 
Vital signs: containment of novel multidrug-resistant organisms and resistance mechanisms – United States, 2006–2017. MMWR Morb Mortal Wkly Rep. 2018 Apr 6;67(13):396–401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5889247</ArticleId>
            <ArticleId IdType="pubmed">29621209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almarzoky Abuhussain SS, Sutherland CA, Nicolau DP.. 
In vitro potency of antipseudomonal β-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals. J Thorac Dis. 2019 May;11(5):1896–1902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6588753</ArticleId>
            <ArticleId IdType="pubmed">31285882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livermore DM.
Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?
Clin Infect Dis. 2002 Mar 1;34(5):634–640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11823954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zowawi HM, Balkhy HH, Walsh TR, et al. . 
β-Lactamase production in key gram-negative pathogen isolates from the Arabian peninsula. Clin Microbiol Rev. 2013 Jul;26(3):361–380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3719487</ArticleId>
            <ArticleId IdType="pubmed">23824364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escandón-Vargas K, Reyes S, Gutiérrez S, et al. . 
The epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther. 2017 Mar;15(3):277–297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27915487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon E-J, Jeong SH.. 
Mobile carbapenemase genes in Pseudomonas aeruginosa. Front Microbiol. 2021 Feb 18;12:614058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7930500</ArticleId>
            <ArticleId IdType="pubmed">33679638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Center for Disease Control and Prevention . 2019 AR Threats Report [Internet]. [cited 2019 May 8]. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Poirel L, Nordmann P, Lagrutta E, et al. . 
Emergence of KPC-producing Pseudomonas aeruginosa in the United States. Antimicrob Agents Chemother. 2010 Jul;54(7):3072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2897310</ArticleId>
            <ArticleId IdType="pubmed">20421402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walters MS, Grass JE, Bulens SN, et al. . 
Carbapenem-resistant Pseudomonas aeruginosa at US Emerging infections program sites, 2015. Emerging Infect Dis. 2019 Jul;25(7):1281–1288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6590762</ArticleId>
            <ArticleId IdType="pubmed">31211681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simner PJ, Opene BNA, Chambers KK, et al. . 
Carbapenemase detection among carbapenem-resistant glucose-nonfermenting gram-negative bacilli. J Clin Microbiol. 2017 Sep;55(9):2858–2864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5648721</ArticleId>
            <ArticleId IdType="pubmed">28701421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grupper M, Sutherland C, Nicolau DP.. 
Multicenter evaluation of ceftazidime-avibactam and ceftolozane-Tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother. 2017 Oct;61(10):e00875–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610483</ArticleId>
            <ArticleId IdType="pubmed">28739780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphries RM, Hindler JA, Wong-Beringer A, et al. . 
Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2017 Dec;61(12):e01858–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5700315</ArticleId>
            <ArticleId IdType="pubmed">28993338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pogue JM, Kaye KS, Veve MP, et al. . 
Ceftolozane/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020 Jul 11;71(2):304–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31545346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hackel MA, Tsuji M, Yamano Y, et al. . 
In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative Bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01968–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5786755</ArticleId>
            <ArticleId IdType="pubmed">29158270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasoo S, Cunningham SA, Cole NC, et al. . 
In vitro activities of Ceftazidime-Avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother. 2015 Dec;59(12):7842–7846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4649150</ArticleId>
            <ArticleId IdType="pubmed">26392487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown AC, Malik S, Huang J, et al. . 
484. Metallo-β-Lactamase-Positive carbapenem-resistant enterobacteriaceae and Pseudomonas aeruginosa in the antibiotic resistance laboratory network, 2017–2018. Open Forum Infect Dis. 2019 Oct 23;6(Supplement_2):S237–S237.</Citation>
        </Reference>
        <Reference>
          <Citation>Li H, Estabrook M, Jacoby GA, et al. . 
In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 2015 Mar;59(3):1789–1793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4325778</ArticleId>
            <ArticleId IdType="pubmed">25534728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simner PJ, Johnson JK, Brasso WB, et al. . 
Multicenter evaluation of the modified Carbapenem inactivation method and the carba NP for detection of Carbapenemase-producing Pseudomonas aeruginosa and acinetobacter baumannii. J Clin Microbiol. 2018;56(1):e01369–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5744225</ArticleId>
            <ArticleId IdType="pubmed">29118172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill CM, Lasko MJ, Asempa TE, et al. . 
Evaluation of the EDTA-modified Carbapenem inactivation method (eCIM) for detecting metallo-β-lactamase-producing Pseudomonas aeruginosa. J Clin Microbiol. 2020 Apr 1;e02015–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7269398</ArticleId>
            <ArticleId IdType="pubmed">32238433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore NM, Li H, Schejbal D, et al. . 
Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCoV reverse transcriptase PCR assay for the detection of SARS-CoV-2. J Clin Microbiol. 2020 Jul 23;58(8):e00938–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7383545</ArticleId>
            <ArticleId IdType="pubmed">32461287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanahashi T, Matsumura Y, Yamamoto M, et al. . 
Comparison of the Xpert Carba-R and NG-test CARBA5 for the detection of carbapenemases in an IMP-type carbapenemase endemic region in Japan. J Infect Chemother. 2021 Mar;27(3):503–506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33214070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill CM, Asempa TE, Tickler IA, et al. . 
Evaluation of the Xpert Carba-R NxG assay for detection of carbapenemase genes in a global challenge set of Pseudomonas aeruginosa isolates. J Clin Microbiol. 2020 Nov 18;58(12):e01098–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7685890</ArticleId>
            <ArticleId IdType="pubmed">33115845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill CM, Asempa TE, Nicolau DP.. 
Development and application of a pragmatic algorithm to guide definitive carbapenemase testing to identify carbapenemase-producing Pseudomonas aeruginosa. Antibiotics (Basel). 2020 Oct 27;9(11):738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7693613</ArticleId>
            <ArticleId IdType="pubmed">33120865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lasko MJ, Gill CM, Asempa TE, et al. . 
EDTA-modified carbapenem inactivation method (eCIM) for detecting IMP metallo-β-lactamase-producing Pseudomonas aeruginosa: an assessment of increasing EDTA concentrations. BMC Microbiol. 2020 Jul 20;20(1):220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7372831</ArticleId>
            <ArticleId IdType="pubmed">32690021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tenover FC, Dela Cruz CM, Dewell S, et al. . 
Does the presence of multiple β-lactamases in gram-negative bacilli impact the results of antimicrobial susceptibility tests and extended-spectrum β-lactamase and carbapenemase confirmation methods?
J Glob Antimicrob Resist. 2020 Sep 2;23:87–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32889141</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
